Citi Reiterates Buy on Johnson & Johnson, Sees JNJ at $285 After FDA Drug Approval

robot
Abstract generation in progress

Citi analyst Joanne Wuensch reiterated a buy rating on Johnson & Johnson and set a $285 price target, implying about 27% upside from the current $225 share price. The bullish call followed FDA approval for Caplyta for prevention of relapse in schizophrenia.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments